Nasdaq IPOs

Chardan Healthcare Acquisition 2, the second blank check company formed by Chardan Capital targeting the healthcare industry, filed on Monday with the SEC to raise up to $85 million in an initial public offering. The New York, NY-based company plans to raise $85 million by offer

Facing record-high volatility and market uncertainty, one biotech is scheduled for the week ahead. Formed by New Enterprise Associate’s orphan drug accelerator Cydan, genetic disorder biotech Imara (IMRA) plans to raise $76 million at a fully diluted $301 million mark

Facing record-high volatility and market uncertainty, one biotech is scheduled for the week ahead. Formed by New Enterprise Associate’s orphan drug accelerator Cydan, genetic disorder biotech Imara (IMRA) plans to raise $76 million at a fully diluted $301 million mark

Facing record-high volatility and market uncertainty, one biotech is scheduled for the week ahead. Formed by New Enterprise Associate’s orphan drug accelerator Cydan, genetic disorder biotech Imara (IMRA) plans to raise $76 million at a $301 million market cap. The Bo

A billion-dollar IPO and two SPACs entered the market this past week, and four IPOs and five SPACs submitted initial filings. The VIX volatility index is still at record-high levels and the turbulent market environment shows no signs of steadying just yet. Waste giant GFL En

A billion-dollar IPO and two SPACs entered the market this past week, and four IPOs and five SPACs submitted initial filings. The VIX volatility index is still at record-high levels and the turbulent market environment shows no signs of steadying just yet. Waste giant GFL En

A billion-dollar IPO and two SPACs entered the market this past week, and four IPOs and five SPACs submitted initial filings. The VIX volatility index is still at record-high levels and the turbulent market environment shows no signs of steadying just yet. Waste giant G

CC Neuberger Principal Holdings I, a blank check company formed by CC Capital and Neuberger Berman, filed on Friday with the SEC to raise up to $300 million in an initial public offering. The New York, NY-based company plans to raise $300 million by offering 30 million units

CC Neuberger Principal Holdings I, a blank check company formed by CC Capital and Neuberger Berman, filed on Friday with the SEC to raise up to $300 million in an initial public offering. The New York, NY-based company plans to raise $300 million by offering 30 million

CC Neuberger Principal Holdings I, a blank check company formed by CC Capital and Neuberger Berman, filed on Friday with the SEC to raise up to $300 million in an initial public offering. The New York, NY-based company plans to raise $300 million by offering 30 million

Lyra Therapeutics, a Phase 2 biotech targeting ear, nose, and throat diseases, filed on Friday with the SEC to raise up to $58 million in an initial public offering. The Watertown, MA-based company was founded in 2005 and plans to list on the Nasdaq under the symbol LYRA. BofA S

Albertsons Companies, a US grocer operating under Albertsons, Safeway, and other banners, filed on Friday with the SEC to raise up to $100 million in an initial public offering. However, this is likely a placeholder for a deal we estimate could raise up to $2 billion. 

Zentalis Pharmaceuticals, a Phase 1/2 biotech developing novel small molecule therapies for various cancers, filed on Friday with the SEC to raise up to $100 million in an initial public offering. The company currently has three product candidates in Phase 1/2 trials and has rai

Albertsons Companies, a US grocer operating under Albertsons, Safeway, and other banners, filed on Friday with the SEC to raise up to $100 million in an initial public offering, though this is likely a placeholder for a deal we estimate could raise up to $2 billion. The

Ayala Pharmaceuticals, a Phase 2 biotech developing small molecule therapies for aggressive cancers, filed on Friday with the SEC to raise up to $50 million in an initial public offering.  The Rehovot, Israel-based company was founded in 2017 and booked $2 million in licensi

Ayala Pharmaceuticals, a Phase 2 biotech developing small molecule therapies for aggressive cancers, filed on Friday with the SEC to raise up to $50 million in an initial public offering.  The Rehovot, Israel-based company was founded in 2017 and booked $2 million in li

Fortress Value Acquisition, a blank check company formed by executives at Fortress Investment Group, filed on Friday with the SEC to raise up to $300 million in an initial public offering. The New York, NY-based company plans to raise $300 million by offering 30 million units at

Fortress Value Acquisition, a blank check company formed by executives at Fortress Investment Group, filed on Friday with the SEC to raise up to $300 million in an initial public offering. The New York, NY-based company plans to raise $300 million by offering 30 million units at

LifeSci Acquisition, a blank check company formed by LifeSci Capital targeting the healthcare industry, raised $60 million by offering 6 million units at $10 at a market cap of $73 million. The company originally planned to offer 5 million units. Each unit consists of one share

Flying Eagle Acquisition, the sixth blank check company formed by SPAC veteran Jeff Sagansky and former MGM CEO Harry Sloan, raised $600 million by offering 60 million units at $10 to command a market value of $725 million. Each unit consists of one whole share of common stock an